Solutions In Silico
Collaboration seeks to use artificial intelligence to predict how patients will respond to immunotherapy
James Strachan |
Protagen AG, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH (all based in Germany) have joined forces in an attempt to improve in silico methods to predict how patients will respond to immunotherapy in malignant melanoma. The group want to develop and apply deep machine-learning to explore biomarkers for relevant endpoints – including clinical response and survival.
To find out more about how the collaboration came about and why a predictive approach to immunotherapy is so important, we spoke with the diagnostics biotechnology company, Protagen.
Enjoy our FREE content!
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Login if you already created an account
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine